微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | -8.43% | -193.73% | -21.29% | 137/159 | 4.1% | 迪哲医药 | 115.44% | 行业排名> |
| 2026-06-30 | -6.95% | -277.72% | -174.7% | 136/159 | 1.36% | 泽璟制药 | 44.02% | 行业排名> |
| 2026-03-31 | -2.53% | -97.66% | 93.11% | 137/159 | 0.06% | 泽璟制药 | 45.29% | 行业排名> |
| 2025-12-31 | -36.7% | -89.47% | -1178.75% | 141/159 | -4.32% | 兴齐眼药 | 38.62% | 行业排名> |
| 2025-09-30 | -2.87% | 29.66% | -55.98% | 119/159 | 1.69% | 兴齐眼药 | 32.91% | 行业排名> |
| 2025-06-30 | -1.84% | 32.1% | -43.75% | 120/159 | 0.34% | 翰宇药业 | 18.95% | 行业排名> |
| 2025-03-31 | -1.28% | 7.91% | 93.39% | 126/159 | -0.34% | 翰宇药业 | 11.39% | 行业排名> |
| 2024-12-31 | -19.37% | -205.52% | -374.75% | 134/159 | -9.4% | 百利天恒 | 181.27% | 行业排名> |
| 2024-09-30 | -4.08% | -574.42% | -50.55% | 127/159 | 4.26% | 百利天恒 | 186.1% | 行业排名> |
| 2024-06-30 | -2.71% | -697.06% | -94.96% | 126/159 | 2.68% | 百利天恒 | 186.89% | 行业排名> |
| 2024-03-31 | -1.39% | -1490% | 78.08% | 124/159 | 2.33% | 百利天恒 | 188.56% | 行业排名> |
| 2023-12-31 | -6.34% | -188.18% | -837.21% | 122/159 | -0.94% | 小方制药 | 41.8% | 行业排名> |
| 2023-09-30 | 0.86% | 82.98% | 352.94% | 109/159 | 2.36% | 拓新药业 | 20.51% | 行业排名> |
| 2023-06-30 | -0.34% | 10.53% | -440% | 118/159 | 1.49% | 拓新药业 | 19.87% | 行业排名> |
| 2023-03-31 | 0.1% | -84.13% | 104.55% | 115/159 | 1.37% | 拓新药业 | 19.91% | 行业排名> |
| 2022-12-31 | -2.2% | 80.36% | -568.09% | 114/159 | 0.84% | 小方制药 | 55.57% | 行业排名> |
| 2022-09-30 | 0.47% | -68.87% | 223.68% | 113/159 | 2.87% | 福元医药 | 25.41% | 行业排名> |
| 2022-06-30 | -0.38% | -156.72% | -160.32% | 118/159 | 2.21% | 小方制药 | 34.81% | 行业排名> |
| 2022-03-31 | 0.63% | 57.5% | 105.63% | 103/159 | 1.59% | 退市金泰 | 10.74% | 行业排名> |
| 2021-12-31 | -11.2% | -109.11% | -841.72% | 130/159 | 0.87% | ST人福 | 6.82% | 行业排名> |
| 2021-09-30 | 1.51% | -27.05% | 125.37% | 108/159 | 4.45% | 小方制药 | 71.99% | 行业排名> |
| 2021-06-30 | 0.67% | -47.24% | 67.5% | 113/159 | 2.99% | 汇宇制药 | 39.25% | 行业排名> |
| 2021-03-31 | 0.4% | -62.96% | 107.47% | 105/159 | 2.48% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-12-31 | -5.36% | -630.3% | -358.74% | 116/159 | 3.82% | 哈三联 | 27.17% | 行业排名> |
| 2020-09-30 | 2.07% | -42.98% | 62.99% | 93/159 | 3.15% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-06-30 | 1.27% | -19.11% | 17.59% | 96/159 | 4.28% | 中哲精化 | 45.32% | 行业排名> |
| 2020-03-31 | 1.08% | -14.29% | 6.93% | 68/159 | 2.23% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-12-31 | 1.01% | -49.8% | -72.18% | 114/159 | 2.62% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-09-30 | 3.63% | 24.74% | 131.21% | 80/159 | 7.58% | 奥赛康 | 35% | 行业排名> |
| 2019-06-30 | 1.57% | 134.33% | 24.6% | 92/159 | 5.02% | 奥赛康 | 28.15% | 行业排名> |
| 2019-03-31 | 1.26% | 44.83% | -37.38% | 78/159 | 2.44% | 宏源药业 | 21.91% | 行业排名> |
| 2018-12-31 | 2.01% | -2.09% | -30.86% | 108/159 | 7.16% | 奥赛康 | 9.7% | 行业排名> |
| 2018-09-30 | 2.91% | 15.94% | 334.33% | 83/159 | 7.2% | 奥赛康 | 40.69% | 行业排名> |
| 2018-06-30 | 0.67% | -68.54% | -22.99% | 97/159 | 4.62% | 信立泰 | 25.93% | 行业排名> |
| 2018-03-31 | 0.87% | 2.35% | -57.66% | 83/159 | 2.57% | 昂利康 | 15.91% | 行业排名> |
| 2017-12-31 | 2.06% | 185.42% | -18.13% | 107/159 | 9.61% | 奥赛康 | 12.08% | 行业排名> |
| 2017-09-30 | 2.51% | -28.69% | 17.84% | 81/159 | 8.3% | 一品红 | 31.62% | 行业排名> |
| 2017-06-30 | 2.13% | 40.13% | 150.59% | 81/159 | 5.55% | 丽珠集团 | 49.43% | 行业排名> |
| 2017-03-31 | 0.85% | 26.87% | 18.06% | 64/159 | 2.11% | 中哲精化 | 54.24% | 行业排名> |
| 2016-12-31 | 0.72% | -78.95% | -79.55% | 101/159 | 6.11% | 华东医药 | 7.2% | 行业排名> |
| 2016-09-30 | 3.52% | 20.14% | 131.58% | 66/159 | 5.7% | ST南新 | 81.7% | 行业排名> |
| 2016-06-30 | 1.52% | -10.59% | 126.87% | 75/159 | 3.56% | 德展健康 | 29.5% | 行业排名> |
| 2016-03-31 | 0.67% | 9.84% | -80.41% | 63/159 | 2.69% | 贝达药业 | 16.78% | 行业排名> |